Pharma

Roche’s $1.5 Billion Punt on Poseida

Roche’s $1.5 billion acquisition of Poseida Therapeutics positions the company to lead the development of scalable, off-the-shelf CAR-T therapies, potentially transforming cancer treatment by improving accessibility, affordability, and targeting both hematologic and solid tumors.

Novo Nordisk’s CagriSema and the Competitive Dynamics in the Obesity Drug Market

Can CagriSema increase the efficacy of obesity treatment and preserve Novo Nordisk's leading position in the market?

FDA Approves NGS-Based Companion Diagnostic for Targeted Therapy in Grade 2 IDH-Mutant Glioma Patients

FDA approves Thermo Fisher's NGS-based companion diagnostic for targeted therapy in patients with grade 2 IDH-mutant glioma

Shockwave Medical Demonstrates Intravascular Lithotripsy's Efficacy for Lower Limb Lesions at VIVA 2024

New clinical data at VIVA 2024 highlights intravascular lithotripsy as a breakthrough treatment for calcified lower limb lesions in peripheral artery disease.

Merck's Keytruda Receives Landmark 30th EU Approval for Two New Indications in Gynecologic Cancers

This latest approval expands Keytruda’s reach to include the treatment of patients with advanced endometrial carcinoma and those with cervical cancer, bolstering options for patients with these hard-to-treat cancers.

AstraZeneca's Wainzua Recommended for EU Approval as New Therapy for Severe Asthma

The drug, Wainzua, specifically targets type 2 inflammation-driven asthma, a form associated with severe, persistent symptoms and significant impairment in quality of life.